SCHEMBL464943

SCHEMBL464943

Cn1c(=O)c2c(nc(N3CCNCC(CO)C3)n2Cc2ccccc2)n(C)c1=O

nearest known ligand 0.77

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 9/20 0.77
ALDH1A1 P00352 7/20 0.62
TSHR P16473 3/20 0.62
MAPT P10636 3/20 0.62
LMNA P02545 3/20 0.62
NPSR1 Q6W5P4 3/20 0.62
MAPK1 P28482 2/20 0.62
RECQL P46063 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.61
TDP1 Q9NUW8 1/20 0.54
USP2 O75604 2/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
HIF1A Q16665 1/20 0.53
ALOX15 P16050 2/20 0.52
HSD17B10 Q99714 2/20 0.52
KDM4E B2RXH2 1/20 0.52
MEN1 O00255 1/20 0.52
HPGD P15428 1/20 0.52
KMT2A Q03164 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5640069 0.90 DPP4 (0.78) DPP4ALDH1A1TSHRMAPTLMNA
SCHEMBL5323627 0.87 DPP4 (1.00) DPP4ALDH1A1TSHRMAPTLMNA
SCHEMBL5641434 0.85 DPP4 (0.73) DPP4ALDH1A1TSHRMAPTLMNA
SCHEMBL5643484 0.85 DPP4 (0.73) DPP4ALDH1A1TSHRMAPTLMNA
SCHEMBL7011952 0.84 DPP4 (0.66) DPP4ALDH1A1TSHRMAPTLMNA
SCHEMBL555986 0.84 DPP4 (0.92) DPP4ALDH1A1TSHRMAPTLMNA
SCHEMBL5639262 0.83 DPP4 (0.61) DPP4ALDH1A1TSHRMAPTLMNA
SCHEMBL5639551 0.82 DPP4 (0.68) DPP4ALDH1A1TSHRMAPTLMNA
SCHEMBL5642868 0.82 DPP4 (0.88) DPP4ALDH1A1TSHRMAPTLMNA
SCHEMBL554778 0.81 DPP4 (0.87) DPP4ALDH1A1TSHRLMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7235538-B2 Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV NOVO NORDISK A/S (DK) 2007-06-26 US claimed
EP-1561752-A1 Heterocyclic compounds that are inhibitors of the enzyme DPP-IV NOVO NORDISK A/S (DK) 2005-08-10 EP claimed
EP-1301187-B1 PURINE-2,6-DIONES WHICH ARE INHIBITORS OF THE ENZYME DIPEPTIDYL PEPTIDASE IV (DPP-IV) NOVO NORDISK AS (DK) 2005-07-06 EP claimed
US-20020161001-A1 Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV NOVO NORDISK A/S (DK) 2002-10-31 US claimed
US-8980322-B2 Controlled release composition TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-03-17 US disclosed
EP-1671649-B1 Dipeptidyl peptidase IV inhibitors for treating diabetic patients with sulfonylurea secondary failure TAKEDA PHARMACEUTICAL (JP) 2011-11-23 EP disclosed
US-7235538-B2 Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV NOVO NORDISK A/S (DK) 2007-06-26 US disclosed
US-7235538-B2 Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV NOVO NORDISK A/S (DK) 2007-06-26 US disclosed
US-7235538-B2 Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV NOVO NORDISK A/S (DK) 2007-06-26 US disclosed
US-20070072810-A1 Agent for treating diabetes TAKEDA PHARMACEUTICAL COMPANY, LIMITED 2007-03-29 US disclosed
EP-1671649-A1 REMEDY FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2006-06-21 EP disclosed
US-20060039974-A1 Sustained release preparation TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-02-23 US disclosed
EP-1607088-A1 CONTROLLED RELEASE COMPOSITION Takeda Pharmaceutical Company Limited (JP) 2005-12-21 EP disclosed
EP-1561752-A1 Heterocyclic compounds that are inhibitors of the enzyme DPP-IV NOVO NORDISK A/S (DK) 2005-08-10 EP disclosed
EP-1301187-B1 PURINE-2,6-DIONES WHICH ARE INHIBITORS OF THE ENZYME DIPEPTIDYL PEPTIDASE IV (DPP-IV) NOVO NORDISK AS (DK) 2005-07-06 EP disclosed
EP-1537880-A1 SUSTAINED RELEASE PREPARATION Takeda Pharmaceutical Company Limited (JP) 2005-06-08 EP disclosed
US-20040034014-A1 Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV KANSTRUP ANDERS BENDTZ (DK) 2004-02-19 US disclosed
EP-1301187-A2 HETEROCYCLIC COMPOUNDS, WHICH ARE INHIBITORS OF THE ENZYME DPP-IV NOVO NORDISK A/S (DK) 2003-04-16 EP disclosed
US-20020161001-A1 Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV NOVO NORDISK A/S (DK) 2002-10-31 US disclosed
WO-2002002560-A2 PURINE-2,6-DIONES WHICH ARE INHIBITORS OF THE ENZYME DIPEPTIDYL PEPTIDASE IV (DPP-IV) NOVO NORDISK A/S (DK) 2002-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034014-A1 Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV DPP4, DPP7, DPP3 DPP4 1/4885ALDH1A1 360/4885TSHR 3443/4885
US-20070072810-A1 Agent for treating diabetes IAPP, DPP4, GLP1R DPP4 2/4885ALDH1A1 2934/4885TSHR 408/4885
US-20020161001-A1 Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV DPP4, DPP7, DPP3 DPP4 1/4885ALDH1A1 360/4885TSHR 3443/4885
US-20060039974-A1 Sustained release preparation DPP4, DPP7, DPP3 DPP4 1/4885ALDH1A1 1224/4885TSHR 2270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.